利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

128 条记录 (耗时 0.034 秒)

    CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS
    4.
    发明申请
    CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS 审中-公开
    含有化合物的胶囊和粉末制剂

    公开(公告)号：US20140178467A1

    公开(公告)日：2014-06-26

    申请号：US14193543

    申请日：2014-02-28

    申请人： SHIRE LLC

    发明人： Roger Withington ,  David Pierce ,  Josephine Christine Ferdinando ,  Peter Neil Davies

    IPC分类号： A61K9/48 ,  A61K33/24

    CPC分类号： A61K33/24 ,  A61K9/14 ,  A61K9/48 ,  A61K9/4825 ,  A61K9/4858 ,  A61K47/02 ,  A61K47/36

    摘要： The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

    摘要翻译： 本发明包括包含壳，碳酸镧或碳酸镧水合物的口服药物胶囊和滑石等润滑剂，其中所述壳包裹碳酸镧或其水合物和润滑剂。 胶囊壳包括例如明胶。 本发明还包括含有碳酸镧或碳酸镧水合物和药学上可接受的赋形剂的口服药物粉末。 可以施用本发明的口服药物胶囊和粉末以治疗处于或患有高血磷症的患者，患有或患有与CKD相关的软组织钙化的风险或患有慢性肾脏疾病（CKD）的风险 ，或患有继发性甲状旁腺功能亢进的风险。

    COMBINATION TREATMENT OF MAJOR DEPRESSIVE DISORDER
    5.
    发明申请
    COMBINATION TREATMENT OF MAJOR DEPRESSIVE DISORDER 审中-公开
    联合治疗主要恶性疾病

    公开(公告)号：US20130217615A1

    公开(公告)日：2013-08-22

    申请号：US13881230

    申请日：2011-10-28

    申请人： Robert A. Lasser ,  Timothy M. Whitaker ,  Jeff Jonas

    发明人： Robert A. Lasser ,  Timothy M. Whitaker ,  Jeff Jonas

    IPC分类号： A61K31/343 ,  A61K31/165 ,  A61K45/06 ,  A61K38/02

    CPC分类号： A61K31/343 ,  A61K31/137 ,  A61K31/165 ,  A61K38/02 ,  A61K45/06 ,  A61K2300/00

    摘要： A method is provided for treating depression, and particularly major depression,by administering an effective amount of an SSRI medication that is augmented by administering an effective amount of an amphetamine prodrug, such as lisdexamfetamine, to patients receiving an SSRI medication. In particular, the amphetamine prodrug is administered to augment the effects of an SSRI medication in patients who respond poorly to the effects of the SSRI medication.

    摘要翻译： 提供了一种通过施用有效量的SSRI药物来治疗抑郁症，特别是主要抑郁症的方法，其通过向接受SSRI药物的患者施用有效量的安非他明前药，例如地西他赛胺而增强。 特别地，施用安非他明前药以增加对SSRI药物效果不佳的患者中SSRI药物的作用。

    PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES
    7.
    发明申请
    PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES 有权
    合成和类似物的制备方法

    公开(公告)号：US20110263850A1

    公开(公告)日：2011-10-27

    申请号：US13132001

    申请日：2009-11-30

    申请人： Bernard Golding

    发明人： Bernard Golding

    IPC分类号： C07D487/04 ,  C07C227/18

    CPC分类号： C07D487/04 ,  C07C201/08 ,  C07C201/12 ,  C07C227/16 ,  C07C227/18 ,  C07C303/28 ,  C07C309/66 ,  C07C229/14 ,  C07C205/44 ,  C07C205/26

    摘要： The present invention relates to a novel process for producing quinazoline compounds which are useful in therapy. More specifically, the compounds produced by the process of the invention are useful in the treatment of a number of cardiovascular diseases. The process of the invention provides 6,7-dichloro-1,5- dihydroimidazo [2,1 -b] quinazolin 2 (3H)-one, more commonly known as anagrelide and its analogues in a clean and efficient manner.

    摘要翻译： 本发明涉及可用于治疗的喹唑啉化合物的新方法。 更具体地，通过本发明的方法生产的化合物可用于治疗许多心血管疾病。 本发明的方法以清洁和有效的方式提供了6,7-二氯-1,5-二氢咪唑并[2,1-b]喹唑啉2（3H） - 酮，更通常称为阿那格雷及其类似物。

    SUBSTITUTED QUINAZOLINES
    8.
    发明申请
    SUBSTITUTED QUINAZOLINES 审中-公开
    取代的喹唑啉

    公开(公告)号：US20110071174A1

    公开(公告)日：2011-03-24

    申请号：US12993064

    申请日：2009-05-13

    申请人： Bernard Golding ,  Richard Franklin

    发明人： Bernard Golding ,  Richard Franklin

    IPC分类号： A61K31/519 ,  C07D239/00 ,  C07D471/04 ,  A61K31/437 ,  A61P7/02 ,  A61P35/00

    CPC分类号： C07D487/04

    摘要： This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.

    摘要翻译： 本发明涉及具有降低心血管副作用潜力的选择性血小板降低剂阿那格雷的取代类似物的发现，其应该导致改善的患者依从性和治疗骨髓增生性疾病的安全性。 更具体地，本发明涉及具有以下通式的某些咪唑并喹唑啉衍生物，其中取代基具有权利要求1中定义的含义，并且其在人体中可用作血小板降低剂。 本发明的化合物通过抑制巨核细胞吞噬作用并因此起血小板的形成的作用。

    Substituted quinazolines
    9.
    发明授权
    Substituted quinazolines 有权
    取代喹唑啉

    公开(公告)号：US07910597B2

    公开(公告)日：2011-03-22

    申请号：US11946572

    申请日：2007-11-28

    申请人： Richard Franklin ,  Bernard T. Golding

    发明人： Richard Franklin ,  Bernard T. Golding

    IPC分类号： A61K31/505 ,  C07D239/00 ,  C07D471/00 ,  C07D487/00 ,  C07D491/00

    CPC分类号： C07D487/04

    摘要： This invention relates to the discovery of 3- and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.

    摘要翻译： 本发明涉及降低心血管副作用潜力的选择性血小板降低剂阿那格雷的3-取代类似物和5-取代的类似物，其应该导致改善患者依从性和治疗骨髓增生性疾病的安全性。 更具体地，本发明涉及某些在人体中作为血小板降低剂具有效用的咪唑并喹唑啉衍生物。 本发明的化合物通过抑制巨核细胞吞噬作用并因此起血小板的形成的作用。